| scholarly article | Q13442814 |
| P50 | author | Cristina Ivan | Q56435654 |
| P2093 | author name string | M Nelson | |
| J Gay | |||
| M J Keating | |||
| V Gandhi | |||
| V K Patel | |||
| J R Marszalek | |||
| K Balakrishnan | |||
| J Morse | |||
| M L Ayres | |||
| W G Wierda | |||
| B Lamothe | |||
| J P Cheung | |||
| P2860 | cites work | Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1 | Q24308005 |
| High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells | Q46055970 | ||
| Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. | Q46074725 | ||
| Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. | Q50893928 | ||
| miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| FOXO transcription factors at the interface between longevity and tumor suppression | Q29620472 | ||
| Regulation of protein stability by GSK3 mediated phosphorylation | Q30437017 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood | Q33774491 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells | Q34354339 | ||
| Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia | Q35022490 | ||
| Chronic lymphocytic leukemia: revelations from the B-cell receptor. | Q35667038 | ||
| Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells | Q35836470 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. | Q36021849 | ||
| Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo | Q36172601 | ||
| Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia | Q36462375 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. | Q36512934 | ||
| Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function | Q36548443 | ||
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study | Q36759124 | ||
| Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling | Q36782109 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Targeting Bruton's tyrosine kinase in B cell malignancies | Q38198490 | ||
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study | Q38956893 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). | Q39065374 | ||
| Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. | Q39414732 | ||
| Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. | Q40916348 | ||
| Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies | Q41524241 | ||
| P433 | issue | 4 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 920-930 | |
| P577 | publication date | 2017-11-03 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy | |
| P478 | volume | 32 |
| Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
| Q91633231 | Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data |
| Q97524840 | Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents |
| Q57029282 | Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies |
| Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
Search more.